| HOME >> MEDICINE >> TECHNOLOGY |
$
,128,895
$
7,350,116Short-term investments
13,730,072
12,863,420Accounts receivable
876,730
467,909Accounts receivable from affiliated entity
39,066
38,406Prepaid expenses and other current assets
760,733
746,049Prepaid expenses and other current assets from affiliated entity
400,890
441,186Total current assets26,936,386
31,907,086Restricted cash
100,146
100,059Fixed assets, net
355,302
295,785Intangible assets, net
8,849,869
9,310,485Goodwill
10,113,371
10,113,371Investment in affiliated entity
8,509,969
9,071,513Investment in common stock warrants
294,000
100,000Other assets
191,913
208,262Total assets$
55,350,956
$
,106,561LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable and accrued expenses
$
3,316,787
$
4,318,942Accounts payable and accrued expenses due to affiliated entity
82,158
20,344Accrued clinical trial expenses
773,769
1,059,372Common stock warrants
8,417,492
5,176,319Deferred revenue
48,739
79,502Deferred revenue from affiliated entity
376,042
388,542Total current liabilities13,014,987
11,043,021Deferred revenue, net of current portion
79,046
80,450Deferred revenue from affiliated entity, net of current portion
1,867,944
1,961,694Deferred rent
80,660
80,875Deferred tax liabilities
78,859
78,859Total liabilities15,121,496
| SOURCE Inovio Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved |